Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results
Cancer
 
Search Results



Your search returned 1870 record(s).

Page 56 of 187  |  Previous Page   |  Next Page

Cancer Type:   Sort By:

This Search was Made Possible by:


  Survival: Patients: Toxicity: Treatment: Hospital: Country: Date:
551 17.0 months Hepatocellular carcinoma 5 Radiation
Hôpital Maisonneuve-Rosemont Canada 5/2013
Treatment Details: Patients: This phase 2 study involved 52 hepatocellular carcinoma patients. The median patient age was 71.3 years and 78.8% were male. Treatment: Patients were treated with a method of
 
552 17.0 months Non-squamous NSCLC 4 Biologic therapy
Chemotherapy
Penn State Milton S, Hershey Medical Center United States 4/2014
Treatment Details: Patients: This phase 2 study involved advanced non-squamous non–small-cell lung cancer patients who were divided into two separate treatment groups. Group A had 55 patients with a median a
 
553 17.0 months Advanced ovarian cancer 4 Chemotherapy
Immunotherapy
Universita` Vita-Salute San Raffaele Italy 6/2012
Treatment Details: Patients: This study involved 37 women with previously treated advanced ovarian cancer. The median patient age was 57 years. Treatment: Patients were treated with the chemotherapy agen
 
554 17.0 months Peripheral T-cell lymphoma 5 Chemotherapy
Hormone
University of Arizona/Arizona Cancer Center United States 7/2012
Treatment Details: Patients: This phase 2 study involved 34 patients with peripheral T-cell lymphoma. The median patient age was 60 years and 67% were male. Treatment: Patients were treated with the chem
 
555 17.0 months Advanced Liver Cancer 3 Biologic therapy
Chemotherapy
Zhong Shan Hospital China 6/2012
Treatment Details: Patients: This study involved advanced hepatocellular carcinoma patients who were divided into two separate treatment groups. Group A consisted of 45 patients with an average age of 51 year
 
556 17.0 months GBM 4 Biologic therapy
Chemotherapy
Harvard Medical School United States 1/2015
Treatment Details: Patients: This phase 2 study involved patients who were divided into groups based on their cancer type. Group A consisted of 24 glioblastoma patients with median age of 53 years; 41.7% were
 
557 16.9 months Mantle cell lymphoma 4 Biologic therapy
Columbia University Medical Center United States 5/2014
Treatment Details: Patients: This phase 2 study involved 58 mantle cell lymphoma patients who were previously treated with bortezomib. The median patient age was 68 years years and 77.6% were male. Treatm
 
558 16.9 months Metastatic, castration-resistant prostate cancer 4 Chemotherapy
Hormone
British Columbia Cancer Agency Canada 8/2010
Treatment Details: Patients: In this study, male patients with metastatic castration-resistance prostate cancer were separated into two treatment groups, called arm A and arm B. Both arms consisted of 41 pat
 
559 16.9 months Recurrent ovarian cancer 5 Biologic therapy
Chemotherapy
Norris Comprehensive Cancer Center United States 1/2008
Treatment Details: Patients: This phase II trial involved 70 women with recurrent ovarian cancer. Their median age was 60 years, ranging from 31 to 83. All had received chemotherapy previously with platinum
 
560 16.8 months Metastatic renal cell carcinoma 4 Biologic therapy
Immunotherapy
Leon Berard Center France 12/2007
Treatment Details: Patients: This study involved 492 patients with metastatic renal cell carcinoma (kidney cancer). The median age was 61, ranging from 33-80 years old. The majority, 75%, were men. Almost
 
Page 56 of 187  | Previous Page  | Next Page